Tomofumi Igarashi

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma

Kensei Tobinai, Yukio Kobayashi, Masaru Narabayashi et al. · Annals of Oncology · 1998 · 151 citations · Full text

B-cell Lymphoma, Lymphoid Neoplasia, Hematological Malignancy +7

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

Tomofumi Igarashi, Yukio Kobayashi, Michinori Ogura et al. · Annals of Oncology · 2002 · 138 citations · Full text

Hematological Malignancy, Indolent B-cell Lymphoma, Progression-free Survival +10

Role of Interleukin-18 and T-helper Type 1 Cytokines in the Development of Mycoplasma pneumoniae Pneumonia in Adults

Hiroshi Tanaka, Mitsuo Narita, Shin Teramoto et al. · CHEST Journal · 2002 · 108 citations

Clinical Immunology, Cytokine, Immunodeficiencies +8

Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

Kensei Tobinai, Tomofumi Igarashi, Kuniaki Itoh et al. · Annals of Oncology · 2004 · 104 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Aggressive B-cell Lymphoma +10

Measurement of bronchial hyperreactivity in infants and preschool children using a new method.

Gyokei Murakami, Tomofumi Igarashi, Yoko Adachi et al. · PubMed · 1990 · 91 citations

Asthma, Neonatology, Pediatric Lung Disease +17